South Carolina's highest court further reduced the penalty against a Johnson & Johnson subsidiary accused of deceptive marketing of an anti-psychotic drug. The decision was to substitute the same verdict the court reached in February in order to correct a "mathematical calculation and to clarify that the unfair trade practices judgment against [Janssen Pharmaceuticals] is supported by federal law," according to the opinion.